The Glenmark Settlement and the Broken Promise of Generic Drugs

Why can the price of a generic drug suddenly skyrocket if multiple companies make the same medicine?

Photo by Alex Green from Pexels

WHEN COMPETITION FAILS THE PEOPLE WHO NEED IT MOST 

Generic drugs are supposed to be one of the greatest success stories in modern healthcare. Once a pharmaceutical patent expires, other manufacturers are allowed to produce similar versions of the same medication, creating competition that typically drives prices sharply downward. Today, generic medicines account for roughly 90 percent of all prescriptions dispensed in the United States while representing only about 13 percent of total drug spending, making them one of the healthcare system's most effective cost-saving mechanisms. Their affordability, however, depends on one critical assumption: that manufacturers actually compete. When that assumption fails, the consequences are not limited to corporate profits. They directly affect patients who rely on affordable medications and have no ability to avoid higher prices. 

The July 15, 2026 settlement between Glenmark Pharmaceuticals and a bipartisan coalition of 49 state attorneys general suggests that this assumption cannot always be taken for granted. Rather than resolving allegations involving a single product or isolated incident, the agreement is part of one of the largest ongoing antitrust investigations ever brought against the generic pharmaceutical industry. Regulators allege that competing manufacturers coordinated prices and rigged bids across more than 100 generic medications, substantially undermining the competitive process that generic drugs are designed to create. 

THE ALLEGED SCHEME BEHIND THE PRICES 

According to investigators, this was not a case of companies independently responding to market conditions. Instead, state attorneys general allege that pharmaceutical executives privately coordinated pricing decisions through secretive meetings in the form of golf outings, dinners, cocktail receptions, and also private phone calls and text messages. The multistate investigation has reviewed more than 20 million documents and communication records, uncovering what regulators describe as a systematic effort to destroy competition.

Image Source: Conversable Economist, 2024. Note: Cartel is used to refer to the relationships between Glenmark Pharmaceuticals and several other organizations, such as Teva Pharmaceuticals, in drug-price manipulation. 

The alleged misconduct extended farther than informal conversations. Investigators claim competing manufacturers agreed on which customers each company would pursue and collectively increased prices at the same periods of time rather than allowing market competition to determine them. In several instances, the states allege that prices for essential generic medications increased by more than 1,000 percent, despite the absence of significant changes in production costs or product quality. Price increases themselves are not evidence of illegal conduct, but agreements among competitors to raise those prices strike at the core of competitive markets. 

Rather than continue litigation, Glenmark agreed to pay $29.668 million, including interest, over the next four years. More importantly, the company agreed to cooperate with ongoing litigation against the 33 remaining corporate defendants and 25 individual pharmaceutical executives who have not yet reached settlements. The agreement also requires Glenmark to strengthen its internal antitrust compliance procedures and report potential future violations to state regulators. 

However, are the financial penalties of this size enough to prevent future misconduct? A $29.7 million payment may appear large, but for a market involving tens to hundreds of billions of dollars in prescription drug spending, it’s questionable whether settlements of this scale truly outweigh the potential benefits companies could gain from years of inflated prices. If the consequences of illegal coordination remain smaller than the rewards, companies may continue viewing enforcement actions as less than a genuine deterrent. 

WHY GENERICS MATTER 

The broader significance of this case lies in the unique role generic drugs play within the healthcare system. Unlike brand-name medicines, generic manufacturers generally compete on price rather than innovation. Because the underlying medicines have already been developed and approved, consumers expect multiple manufacturers entering the market to lower prices through competition. That expectation benefits not only patients, but also insurers, employers, Medicare, and Medicaid, all of which rely on affordable generic medicines to control healthcare spending. 

When competition breaks down, however, those savings quickly disappear. The generic drug market depends on a simple economic principle: many manufacturers competing for the same consumers should force prices downward. If companies instead coordinate behind closed doors, consumers are left with the costs of a competitive market without receiving the benefits. Higher generic drug prices affect the entire healthcare system, particularly increasing insurance costs and out-of-pocket expenses for patients. Unlike luxury goods or discretionary purchases, prescription medications are often unavoidable expenses. Patients can’t just delay purchasing life-saving insulin or antibiotics because prices have increased. This makes pharmaceutical

price coordination especially damaging because consumers are often trapped in the market rather than free to walk away from it. The economic consequences therefore extend well beyond individual pharmacies, affecting healthcare affordability across the country. 

LOOKING AHEAD 

The Glenmark settlement is important not because of its nearly $30 million payment, but because of what it signals about the future of competition in pharmaceutical markets. By requiring Glenmark to cooperate against dozens of remaining defendants, regulators are treating this agreement not just as the end of the investigation, but also as a step in uncovering the full scope of the scheme. The outcome of the remaining litigation could determine how authorities approach generic drug markets for years to come. 

Perhaps the most important lesson is that competition cannot be judged simply by counting the number of firms in a market. On paper, the generic pharmaceutical industry appears highly competitive, with multiple manufacturers producing identical medicines after patents expire. Yet if competitors coordinate prices instead of competing against one another, that competition exists only in appearance. The Glenmark settlement is an important reminder that protecting consumers requires more than discovering illegal conduct after the damage has occurred. It requires creating consequences strong enough that companies think twice before replacing competition with coordination. 

---

Takedowns is a weekly column by Katya Chikanov examining major antitrust settlements across industries and what they reveal about market competition and economic policy.